HIV Treatment: Understanding Antiretroviral Therapy (ART)
Antiretroviral therapy (ART) is the standard of care for HIV. It combines three or more antiretroviral (ARV) drugs from at least two different classes to maximally suppress viral replication. Effective ART reduces plasma HIV RNA (viral load) to undetectable levels (typically <50 copies/mL), preserves or restores CD4+ T-cell counts, prevents AIDS-defining illnesses, and eliminates sexual transmission risk (U=U: Undetectable = Untransmittable).
Six Main ARV Drug Classes
- NRTIs/NtRTIs (Nucleoside/tide Reverse Transcriptase Inhibitors): Faulty building blocks that terminate viral DNA chain elongation. Backbone of most regimens. Examples: tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC), lamivudine (3TC), abacavir (ABC), zidovudine (ZDV).
- NNRTIs (Non-nucleoside RTIs): Allosterically bind and inhibit reverse transcriptase. Examples: efavirenz (EFV), rilpivirine (RPV), doravirine (DOR), etravirine (ETR), nevirapine (NVP).
- PIs (Protease Inhibitors): Block HIV protease, preventing cleavage of viral polyproteins into functional proteins. Usually boosted with ritonavir (RTV) or cobicistat (COBI) to increase levels. Examples: darunavir (DRV), atazanavir (ATV), lopinavir (LPV).
- INSTIs (Integrase Strand Transfer Inhibitors): Block integrase, preventing viral DNA integration into host genome. Current preferred class for most patients—high efficacy, high barrier to resistance, favorable tolerability. Examples: dolutegravir (DTG), bictegravir (BIC), raltegravir (RAL), cabotegravir (CAB, long-acting).
- Entry/Fusion Inhibitors: Prevent viral entry into CD4+ cells. Enfuvirtide (T-20, injectable fusion inhibitor), maraviroc (MVC, CCR5 antagonist—see below).
- CCR5 Antagonists: Block CCR5 co-receptor used by R5-tropic HIV strains. Maraviroc only; requires tropism testing. Used in salvage regimens.
Key Treatment Principles
- Combination therapy: ≥3 drugs from ≥2 classes to prevent resistance.
- Preferred initial regimens (per DHHS/IAS-USA guidelines): INSTI + 2 NRTIs (e.g., BIC/FTC/TAF, DTG/3TC, DTG + TDF/FTC or TAF/FTC).
- Drug selection based on: Viral load, resistance testing (baseline genotypes), HLA-B*5701 (abacavir hypersensitivity), renal/hepatic function, comorbidities, drug interactions, pregnancy potential, adherence barriers, cost/access.
- ART is lifelong: Does not cure HIV (latent reservoirs persist). Strict adherence is essential—missed doses allow resistance.
- Monitoring: Viral load at 4–8 weeks, then every 3–6 months once suppressed. CD4 count every 3–6 months initially, then less frequently if stable. Renal/hepatic/metabolic monitoring per regimen.
- Switching/simplification: For toxicity, simplification, drug interactions, or patient preference—always maintain viral suppression.
With modern ART, people with HIV can live near-normal lifespans. The key is early diagnosis, rapid linkage to care, and sustained adherence.
HIV & AIDS - Related Articles
- HIV & AIDS: Understanding the Connection and Immune System Impact
- HIV/AIDS Origins: Debunking Conspiracy Theories & Exploring Scientific Evidence
- HIV & AIDS for Teens: Understanding Transmission & Prevention
- HIV Transmission Risk With an Uninfected Partner: Effectively Zero
- Understanding AIDS: Symptoms, Causes, and Diagnosis
- HIV Clinical Latency: Duration, Progression, and Modern Treatment Outcomes
- HIV/AIDS & Life Expectancy: The Transformation With Modern Treatment
